On Thursday, Wolfe Research issued simultaneous upgrades for both Biogen and AbbVie, elevating each to Outperform status with identical $300 price targets. The analyst firm cited robust drug development pipelines, compelling market valuations, and anticipated clinical trial results as primary catalysts.
Biogen shares have been trading below broader market valuations, a disconnect that Wolfe Research believes fails to capture the true potential of its development portfolio. The firm upgraded from Peer Perform while establishing a $300 price objective.
Wolfe’s bullish thesis centers on two promising therapeutics. Litifilimab has the potential to become the inaugural biologic treatment approved for cutaneous lupus erythematosus. Meanwhile, felzartamab could target antibody-mediated rejection in a market opportunity that analysts may be underestimating.
The company’s recent acquisition of Apellis Pharmaceuticals bolsters its immediate revenue outlook through two commercialized products, Empaveli and Syfovre.
Financial performance exceeded market projections in the latest reporting period. The company delivered earnings per share of $3.60 compared to the $2.94 Wall Street consensus, while revenues reached $2.74 billion, marking a 3.4% year-over-year increase. Management has established full-year 2026 EPS guidance between $12.00 and $13.00.
Institutional investors hold 87.93% of Biogen’s outstanding shares. During the second quarter, Handelsbanken Fonder increased its position by 12.7%, now owning 93,236 shares valued at approximately $20.14 million.
Analysts maintain a Moderate Buy consensus on the stock, with an average target price of $224.61. Trading commenced Thursday at $208.87, approaching the 52-week peak of $219.72.
Wolfe similarly upgraded AbbVie from Peer Perform to Outperform. Analysts argued that AbbVie’s forward 2027 price-to-earnings multiple of 14.6 times appears undervalued for a pharmaceutical company positioned to achieve high-single-digit revenue expansion throughout the remainder of the decade.
Patent protection represents a critical component of the upgrade rationale. Generic competition for Rinvoq has been delayed until 2037, while AbbVie continues to vigorously defend Skyrizi’s intellectual property rights. This extended protection timeline could shield the company from significant patent cliff risks during the current decade.
Second-quarter financial results showed revenue of $16.99 billion, reflecting a 10.2% annual increase and exceeding the $16.80 billion analyst consensus. Earnings per share reached $3.65, marginally beating the $3.61 forecast.
Skyrizi and Rinvoq continue serving as the company’s primary growth engines. Additionally, Canada’s Drug Agency issued a positive reimbursement recommendation for Ubrelvy in acute migraine therapy, creating another potential revenue opportunity.
Shareholders recently approved the company’s acquisition of Apogee Therapeutics, though the deal introduces approximately $8 billion in additional debt, which certain analysts have identified as a potential execution challenge.
Wall Street maintains a Moderate Buy consensus rating on AbbVie with an average price target of $274.33. Shares opened Thursday’s session at $249.12.
The post Biogen (BIIB) and AbbVie (ABBV) Receive Rare Double Upgrades: What Investors Need to Know appeared first on Blockonomi.
